-
Industry | Biotechnology |
---|---|
Sector | Healthcare |
ISIN | US74319F1075 |
CurrencyCode | USD |
Exchange | NASDAQ |
Beta | 1.19 |
---|---|
Dividend Yield | 0.0% |
Target Price | 5 |
PE Ratio | None |
Market Cap | 76M |
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIOR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024